FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2165562685> ?p ?o ?g. }

• W2165562685 abstract "Over recent years a number of novel therapies have shown promise in advanced renal cell carcinoma (RCC). Internationally the standard of care of first-line therapy is sunitinib™, after a clear survival benefit was demonstrated over interferon-α. Convention dictates that sunitinib is continued until evidence of disease progression, assuming tolerability, although there is no evidence that this approach is superior to intermittent periods of treatment. The purpose of the STAR trial is to compare the standard treatment strategy (conventional continuation strategy, CCS) with a novel drug free interval strategy (DFIS) which includes planned treatment breaks.The STAR trial is an NIHR HTA-funded UK pragmatic randomised phase II/III clinical trial in the first-line treatment of advanced RCC. Participants will be randomised (1:1) to either a sunitinib CCS or a DFIS. The overall aim of the trial is to determine whether a DFIS is non-inferior, in terms of 2-year overall survival (OS) and quality adjusted life years (QALY) (averaged over treatment and follow up), compared to a CCS. The QALY primary endpoint was selected to assess whether any detriment in terms of OS could be balanced with improvements in quality of life (QoL). This is a complex trial with a number of design challenges, and to address these issues a feasibility stage is incorporated into the trial design. Predetermined recruitment (stage A) and efficacy (stage B) intermediary endpoints must be met to allow continuation to the overall phase III trial (stage C). An integral qualitative patient preference and understanding study will occur alongside the feasibility stage to investigate patients' feelings regarding participation or non-participation in the trial.The optimal duration of continuing sunitinib in advanced RCC is unknown. Novel targeted therapies do not always have the same constraints to treatment duration as standard chemotherapeutic agents and currently there are no randomised data comparing different treatment durations. Incorporating planned treatment breaks has the potential to improve QoL and cost effectiveness, hopefully without significant detriment on OS, as has been demonstrated in other cancer types with other treatments.Controlled-trials.com ISRCTN 06473203." @default.
• W2165562685 created "2016-06-24" @default.
• W2165562685 creator A5001515663 @default.
• W2165562685 creator A5006195407 @default.
• W2165562685 creator A5006273372 @default.
• W2165562685 creator A5010936863 @default.
• W2165562685 creator A5017165070 @default.
• W2165562685 creator A5028785475 @default.
• W2165562685 creator A5040908788 @default.
• W2165562685 creator A5042875511 @default.
• W2165562685 creator A5046944970 @default.
• W2165562685 creator A5046999320 @default.
• W2165562685 creator A5052802770 @default.
• W2165562685 creator A5054778664 @default.
• W2165562685 creator A5056951639 @default.
• W2165562685 creator A5086212361 @default.
• W2165562685 date "2012-12-01" @default.
• W2165562685 modified "2023-09-28" @default.
• W2165562685 title "The STAR trial protocol: a randomised multi-stage phase II/III study of Sunitinib comparing temporary cessation with allowing continuation, at the time of maximal radiological response, in the first-line treatment of locally advanced/metastatic Renal Cancer" @default.
• W2165562685 cites W1924428325 @default.
• W2165562685 cites W1998925731 @default.
• W2165562685 cites W2015805367 @default.
• W2165562685 cites W2045992174 @default.
• W2165562685 cites W2074256954 @default.
• W2165562685 cites W2096685635 @default.
• W2165562685 cites W2097147116 @default.
• W2165562685 cites W2099088585 @default.
• W2165562685 cites W2105258029 @default.
• W2165562685 cites W2106475544 @default.
• W2165562685 cites W2109498035 @default.
• W2165562685 cites W2124440635 @default.
• W2165562685 cites W2124451268 @default.
• W2165562685 cites W2143813821 @default.
• W2165562685 cites W2144690940 @default.
• W2165562685 cites W2145220058 @default.
• W2165562685 cites W2146860018 @default.
• W2165562685 cites W2149026055 @default.
• W2165562685 cites W2149456801 @default.
• W2165562685 cites W2153836018 @default.
• W2165562685 cites W2160120519 @default.
• W2165562685 cites W2162090934 @default.
• W2165562685 cites W2165837521 @default.
• W2165562685 doi "https://doi.org/10.1186/1471-2407-12-598" @default.
• W2165562685 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3583710" @default.
• W2165562685 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23241439" @default.
• W2165562685 hasPublicationYear "2012" @default.
• W2165562685 type Work @default.
• W2165562685 sameAs 2165562685 @default.
• W2165562685 citedByCount "26" @default.
• W2165562685 countsByYear W21655626852013 @default.
• W2165562685 countsByYear W21655626852014 @default.
• W2165562685 countsByYear W21655626852015 @default.
• W2165562685 countsByYear W21655626852016 @default.
• W2165562685 countsByYear W21655626852017 @default.
• W2165562685 countsByYear W21655626852018 @default.
• W2165562685 countsByYear W21655626852019 @default.
• W2165562685 countsByYear W21655626852020 @default.
• W2165562685 countsByYear W21655626852021 @default.
• W2165562685 countsByYear W21655626852023 @default.
• W2165562685 crossrefType "journal-article" @default.
• W2165562685 hasAuthorship W2165562685A5001515663 @default.
• W2165562685 hasAuthorship W2165562685A5006195407 @default.
• W2165562685 hasAuthorship W2165562685A5006273372 @default.
• W2165562685 hasAuthorship W2165562685A5010936863 @default.
• W2165562685 hasAuthorship W2165562685A5017165070 @default.
• W2165562685 hasAuthorship W2165562685A5028785475 @default.
• W2165562685 hasAuthorship W2165562685A5040908788 @default.
• W2165562685 hasAuthorship W2165562685A5042875511 @default.
• W2165562685 hasAuthorship W2165562685A5046944970 @default.
• W2165562685 hasAuthorship W2165562685A5046999320 @default.
• W2165562685 hasAuthorship W2165562685A5052802770 @default.
• W2165562685 hasAuthorship W2165562685A5054778664 @default.
• W2165562685 hasAuthorship W2165562685A5056951639 @default.
• W2165562685 hasAuthorship W2165562685A5086212361 @default.
• W2165562685 hasBestOaLocation W21655626851 @default.
• W2165562685 hasConcept C126322002 @default.
• W2165562685 hasConcept C143998085 @default.
• W2165562685 hasConcept C159110408 @default.
• W2165562685 hasConcept C168563851 @default.
• W2165562685 hasConcept C197934379 @default.
• W2165562685 hasConcept C203092338 @default.
• W2165562685 hasConcept C2777472916 @default.
• W2165562685 hasConcept C2778375690 @default.
• W2165562685 hasConcept C2779490328 @default.
• W2165562685 hasConcept C2779951463 @default.
• W2165562685 hasConcept C535046627 @default.
• W2165562685 hasConcept C71924100 @default.
• W2165562685 hasConceptScore W2165562685C126322002 @default.
• W2165562685 hasConceptScore W2165562685C143998085 @default.
• W2165562685 hasConceptScore W2165562685C159110408 @default.
• W2165562685 hasConceptScore W2165562685C168563851 @default.
• W2165562685 hasConceptScore W2165562685C197934379 @default.
• W2165562685 hasConceptScore W2165562685C203092338 @default.
• W2165562685 hasConceptScore W2165562685C2777472916 @default.
• W2165562685 hasConceptScore W2165562685C2778375690 @default.
• W2165562685 hasConceptScore W2165562685C2779490328 @default.
• W2165562685 hasConceptScore W2165562685C2779951463 @default.
• W2165562685 hasConceptScore W2165562685C535046627 @default.
• W2165562685 hasConceptScore W2165562685C71924100 @default.
• W2165562685 hasIssue "1" @default.

• next